Knowledge Distillery

In this paper, the authors report a patient treated with natalizumab for relapsing-remitting MS who developed COVID-19 and recovered in a few days…

Cognitive decline among individuals with history of mild symptomatic SARS‐CoV‐2 infection. A longitudinal prospective study nested to a population…

This study aimed to explore the associations of objective cognitive performances and psychological distress with cognitive complaints in COVID-19…

In this case report recently published in Neurology, Barzegar et al. present the case of a 42-year-old woman affected by relapsing-remitting MS…

Acute‐onset delirium in intensive care COVID patients: association of imperfect brain repair with foodborne micro‐pollutants

The objective of this study was to explore the perceived impact of confinement in patients with Parkinson's disease and document the effects of gender…

In this retrospective multicentre cohort study, just published in JAMA, the authors describe the association between use of hydroxychloroquine, with…

Disease‐modifying therapies and coronavirus disease 2019 severity in multiple sclerosis

In this ongoing trial, the authors randomly assigned 44,165 participants aged 16 or older and 2,264 participants aged 12-15 to receive two 30-μg…

In this multicentre, prospective, open-label, randomised, phase 2 trial the authors assessed the efficacy and safety of combined interferon beta-1b,…

Incidence and impact of COVID-19 in MS. A survey from a Barcelona MS unit

In this study the authors investigated the effect of vaccination of health care workers in Scotland on the risk of coronavirus disease 2019 (COVID-19)…